Lexicon Pharmaceuticals, Inc. Loss Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Submit Transaction Detail Now (Optional)

- OR -

    This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

    FAX: 212-363-7171

    TOLL FREE: 877-363-5972

    Levi & Korsinsky announces it has commenced an investigation of Lexicon Pharmaceuticals, Inc. (“Lexicon” or “the Company”) (NASDAQGS: LXRX) concerning possible violations of federal securities laws.

    On January 17, 2019, Lexicon announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration had “voted eight to eight on the question of whether the overall benefits of [Lexicon’s product] Zynquista (sotagliflozin) outweighed the risks to support approval.” On news of the advisory committee’s stalemate, Lexicon’s stock price fell $1.74 per share, or 22.6%, to close at $5.96 per share on January 18, 2019.